PA
XBI icon

Para Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Para Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-20,000
Closed -$1.03M – 15
2016
Q1 		$1.03M Buy
+20,000
New +$1.04M 3.89% 5

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Para Advisors's XBI Position: Q2 2016 in Review

Para Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2016, closing a stake of 20,000 shares — an estimated $1.03M sold.

Para Advisors first reported a position in XBI in Q1 2016 and held it in 1 quarter. The position peaked at $1.03M in Q1 2016. 201 funds tracked by Wall St. Rank hold XBI as of Q2 2016.

  • Para Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2016 after selling out during the quarter.
  • Para Advisors sold 20,000 State Street SPDR S&P Biotech ETF shares in Q2 2016, an estimated $1.03M.
  • Para Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and held it in 1 quarter.
  • Para Advisors's State Street SPDR S&P Biotech ETF position peaked at $1.03M in Q1 2016.
  • 201 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2016.

Based on Para Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.